Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

5.500 +0.100 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Curevac N.V.

< Previous 1 2 3 4 5 6 Next >
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates
Following the market opening Tuesday, the Dow traded down 0.16% to 34,574.38 while the NASDAQ rose 0.32% to 13,926.79. The S&P also fell, dropping 0.04% to 4,224.95. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Could CureVac Be a Millionaire-Maker Stock?
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in. 
Via The Motley Fool
Exposures COVID-19
Why CureVac's Stock Is Trading Higher Today
CureVac (NASDAQ:CVAC) shares are trading higher ... 
Via Benzinga
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
Exposures COVID-19
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-... 
Via Benzinga
Exposures COVID-19
What's Up WIth BioNTech Stock And CureVac Stock Today?
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to... 
Via Benzinga
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
Exposures COVID-19
56 Stocks Moving In Friday's Mid-Day Session
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:... 
Via Benzinga
Bill And Melinda Gates' Divorce News A Bull Case For GameStop? What You Need To Know
A post by a member of the Reddit investor forum r/GME in March that speculated billionaires were increasing their short positions in GameSt... 
Via Benzinga
CureVac's Vaccine Might Protect Against the South African Variant
The promising data in mice needs to translate into humans. 
Via The Motley Fool
Exposures COVID-19
Could These 3 Brilliant mRNA Stocks Make You Millions?
Probably not, but at least one of them could make you thousands over time. 
Via The Motley Fool
Exposures COVID-19
Best Biotech Stocks & ETFs for mRNA, Gene Editing
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
CureVac's Potential Has Wall Street Sending Mixed Signals
The biotech still has a long way to go to prove itself and justify its current stock valuation. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
Upgrades Susquehanna upgraded the previous rating for Axalta Coating Systems Ltd (NYSE:AXTA) from Neutral to Positive. The current stock performance of Axalta Coating Sys... 
Via Benzinga
2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share
A big market is in big need of more vaccines. 
Via The Motley Fool
Exposures COVID-19
7 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
CureVac (CVAC) Q4 2020 Earnings Call Transcript
CVAC earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today
PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday. PPD... 
Via Benzinga
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) rose 25.1% to $0.6485 in pre-market trading. Bit Digital, Inc. (NASDAQ: BTBT) rose 15.1% to $16.40 in pre-market trading after... 
Via Benzinga
Earnings Scheduled For April 15, 2021
Companies Reporting Before The Bell • Charles Schwab (NYSE:SCHW) is projected to report quarterly earnings at $0.82 per share on revenue of $4.58 billion. •... 
Via Benzinga
UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots
Researchers said that a U.K. study of using different Covid-19 vaccines in two-dose inoculations is now expanded to include vaccines made by Moderna Inc (NASDAQ: ... 
Via Benzinga
Exposures COVID-19
South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report
According to a real-world data study in Israel, the coronavirus variant discovered in South Africa may dodge the protection provided by Pfizer Inc (NYSE: PFE) /... 
Via Benzinga
Exposures COVID-19
Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC
The British government and health experts in the country have come forward to defend the COVID-19 vaccine developed by AstraZeneca plc’s (NASDAQ: AZN) and... 
Via Benzinga
Exposures COVID-19
Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.